Cognitive Systems Launches Caregiver Aware, Enabling Service Providers to Enter the Remote Eldercare Industry
4.5.2022 14:50:00 EEST | Business Wire | Press release
Cognitive Systems Corp. announced today the launch of Caregiver Aware, a revolutionary advancement in preventative health. Working directly with service providers during development to understand their challenges, Caregiver Aware was designed with flexible go-to-market options that leverage providers’ existing infrastructure and hardware. Building on the success of its Home Aware security product that commercially launched in 2019, Caregiver Aware’s predictive analytics has the potential to significantly disrupt the broadband services market and our definition of “smart home.”
Caregiver Aware is powered by WiFi Motion™, which is currently active in over 70 countries and leverages connected IoT devices to transform the entire home into a motion-sensing network without additional hardware. It is an end-to-end solution featuring Cognitive Systems' patented algorithms, clean iOS and Android app interfaces. Backed by robust integration support from Cognitive’s QA and commercialization experts, the optimized data management system does not impact broadband performance. This launch represents a key moment for service providers looking to enter the rapidly growing field of remote eldercare by providing their customers with a tool for aging in place.
“Technology is accelerating the shift from reactive to proactive healthcare and we want to help lead that charge,” said Taj Manku, co-founder and CEO of Cognitive Systems. “Caregiver Aware has been on our product roadmap from the start, but the pandemic has made us all acutely aware of the need for innovation in preventative health. Our goal with this product is to create a bridge for service providers to build a care-focused ecosystem using data analytics, which will be a game-changing step in shaping future broadband services.”
Caregiver Aware is currently being trialed with service provider partners. It allows caregivers to complete remote wellness checks and view live motion in a loved one's home without intruding on their privacy or independence in the way cameras or wearable devices do. This launch represents the tip of the iceberg for remote eldercare monitoring, with new features already in development aimed at capturing behavioural patterns based on natural motion AI, improving localization and enabling customized notifications.
“As we worked towards a full-scale launch with more advanced features, user feedback confirmed immediate value in providing people with the peace of mind knowing a loved one is home, safe and active,” says Amanda Forsyth, Director of Product Management at Cognitive Systems. “This first iteration of Caregiver Aware is an important steppingstone towards a proactive health model and, with the majority of adults wanting to age in place, Caregiver Aware not only fills an industry need but a societal one.”
With aging populations around the world, the remote eldercare industry is poised to take off. However, with current world events and chip shortages, integration timelines can be lengthy. Service providers looking to enter the market need to start conversations now about where care solutions fit into their product roadmaps.
Learn more about how WiFi Sensing is ushering in a new era of preventative healthcare here.
About Cognitive Systems
Cognitive Systems Corp. is on a mission to transform the way WiFi networks are used. Its flagship technology, WiFi Motion™, uses wireless signals to sense motion in the home. WiFi Motion harnesses artificial intelligence and predictive analytics to reliably identify and localize motion for the smart home, home monitoring, and wellness monitoring markets. This patented technology is layered onto existing WiFi networks without additional hardware to enhance service provider and router manufacturer offerings.
www.cognitivesystems.com
https://www.linkedin.com/company/cognitive-systems-corp-/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220504005187/en/
Contact information
Press
Proof Strategies
Jillian Colucci
jcolucci@getproof.com
416-801-9851
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
European Commission Approves DAYBU ® (trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms of Rett Syndrome in the European Union24.8.2026 10:01:00 EEST | Press release
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the European Commission (EC) has granted marketing authorization for DAYBU (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older, making it the first and only treatment approved for Rett syndrome in the European Union (EU). “The approval of DAYBU marks a significant milestone for the Rett syndrome community in the EU and advances our mission to bring this innovative treatment to patients and families who have long faced a profound unmet medical need,” said Catherine Owen Adams, Acadia’s Chief Executive Officer. “For people living with Rett syndrome, a devastating rare neurodevelopmental disorder, there have been no approved treatment options in the EU. We are proud to make DAYBU available and look forward to supporting patients, caregivers, and healthcare providers gain access to treatment." The DAYBU marketing authorization in the EU is prim
ORZEYFUL (oveporexton) Approved in Japan as the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 124.8.2026 09:36:00 EEST | Press release
Takeda (TOKYO:4502/NYSE:TAK) announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) approved the use of ORZEYFUL (oveporexton) for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults. ORZEYFUL is a first-in-class oral orexin receptor 2 (OX2R) agonist and the only medicine indicated in Japan to treat the disease holistically rather than individual symptoms. The discovery of this new class of medicine originated in Takeda's laboratories in Japan. Takeda is proceeding with launch preparations and expects to make ORZEYFUL available as quickly as possible. “Our discovery of the first orexin agonist is a successful representation of Japan-originated science that will directly impact people around the world living with narcolepsy type 1,” said Julie Kim, president and chief executive officer of Takeda. “With the potential to redefine narcolepsy type 1 care, ORZEYFUL is the first validation of our broader orexin strategy, demonstrating how scientifi
Fasset Hits $1B Valuation as SBI Group Leads $68M Series C to Scale AI-Powered Stablecoin Neobanking24.8.2026 09:03:00 EEST | Press release
Fasset, the AI-powered stablecoin neobanking platform, today announced it has raised $68 million in Series C funding at a $1 billion valuation. The financing was led by SBI Group and follows Fasset’s $51 million Series B earlier this year, which brought Speedinvest onto the cap table alongside a group of strategic investors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260823503947/en/ Mohammad Raafi Hossain, Co-Founder and CEO, Fasset The new capital will support the expansion of Own Network, Fasset’s regulated financial network that connects banks, telcos, payment and liquidity providers to enable settlement across international markets. Fasset will also increase investment in agentic AI-enabled systems supporting corridor banking, stablecoin settlement and tokenized asset infrastructure. After raising Series B in May, Fasset has now raised a total of $119 million in 2026. The financing marks Fasset’s entry into the glob
Zanders Expands DACH Region with New Office in Vienna, Austria24.8.2026 08:11:00 EEST | Press release
Zanders, the global treasury, risk, and technology consultancy, today announced a significant expansion of its DACH region with the opening of a new office in Vienna. The move builds on Zanders' continued growth across Germany, Austria, and Switzerland, and marks another step in the firm's strategy of deepening its presence in the markets where client demand for specialized treasury, risk, and corporate finance advisory is growing fastest. DACH has been one of Zanders' priority regions for several years, with the firm steadily expanding its team and client base across Germany and Switzerland. Austria represents a natural next step in that growth: in conversations with clients in the market, Zanders has seen growing interest in treasury transformation and financing support, as companies work through interest rate volatility, refinancing needs, and a broader shift toward more digitized, centralized treasury operations. The new Vienna office allows Zanders to be closer to clients' operati
Novotech Strengthens Presence in Japan with Opening of Tokyo Office24.8.2026 02:01:00 EEST | Press release
Novotech, a leading global biotech CRO and full-service clinical research organization, has strengthened its established presence in Japan with the opening of a new office in Tokyo. The investment builds on Novotech’s existing operations and clinical trial activity in Japan and further enhances its ability to support Japanese biopharma companies as they advance programs regionally and across key international markets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260823592174/en/ Takeshi Mori, Novotech Country Head, Japan The Tokyo office will serve as a strategic hub for Novotech’s growing operations in Japan, providing enhanced local expertise and strengthening collaboration with clients, partners, research institutions, and innovation ecosystems across the region. Novotech is currently supporting ongoing studies in Japan and provides sponsors with integrated support across early-phase clinical development in Australia, F
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom